Trial · NCT03842631
Optimizing Timolol Maleate Treatment of Infantile Hemangioma by Doppler Ultrasound Examination
NCT03842631, Unknown, XiaoXi Lin
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Optimizing Timolol Maleate Treatment of Infantile Hemangioma by Doppler Ultrasound Examination. Trials, record NCT03842631. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03842631
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Optimizing Timolol Maleate Treatment of Infantile Hemangioma by Doppler Ultrasound Examination
- NCT number
- NCT03842631
- Status
- Unknown
- Enrollment
- 150 participants, estimated
- Lead sponsor
- XiaoXi Lin
- Conditions
- Infantile Hemangioma
- Interventions
- Timolol Maleate 0.5% Oph Soln
- First posted
- 2019-02-15
- Last updated
- 2019-02-19
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Depth of infantile hemangioma | through study completion, an average of 1 year | At the beginning of treatment, the thickness of hemangioma was measured by b-mode ultrasound at each follow-up. |
| Secondary | Color | through study completion, an average of 1 year | The redness of lesion is measured by standard photography. |
| Secondary | Dimensions | through study completion, an average of 1 year | The dimension of lesion is measured by standard photography. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03842631
GET https://conductscience.org/api/trials/v1/NCT03842631/registered